A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

NCT04856917 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Acne Vulgaris

Interventions

DRUG: Imsidolimab
BIOLOGICAL: Placebo

Sponsor

Vanda Pharmaceuticals